ADVERTISEMENT
Latest Blogs, Articles, and More
Firstline Kadcyla Results Disappointing in HER2-Positive Metastatic Breast Cancer Trial
Two HER2-targeting regimens anchored by Kadcyla (T-DM1) failed to outperform the standard strategy of Herceptin plus chemotherapy in women newly diagnosed with advanced HER2-positive breast cancer.
Subtype of Triple-Negative Breast Cancer Responds to Neoadjuvant Avastin
The addition of Avastin (bevacizumab) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rates in women with basal-like breast cancer compared with non-basal-like subtypes.
Live in the Moment: A Lesson From Cancer. And Preschoolers.
Learning to cope with a cancer diagnosis is an ongoing process. Coming face to face with death forces one to reexamine what is really important.
Somatuline Depot Approved for Gastroenteropancreatic Neuroendocrine Tumors
The Food and Drug Administration has approved Somatuline Depot (lanreotide) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), based on findings from the phase 3 CLARINET study.
Upfront Faslodex Improves Survival Over Anastrozole in Estrogen-Positive Metastatic Breast Cancer
Faslodex (fulvestrant) improved overall survival by nearly six months compared with anastrozole as initial hormone therapy for postmenopausal women with estrogen receptor-positive advanced breast cancer, according to findings from the phase 2 FIRST trial.
Special Feature
ADVERTISEMENT
ADVERTISEMENT
$auto_registration$